SCM
ALXN

Silverarc Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Silverarc Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$781K – 109
2020
Q4 		$781K Buy
+5,000
New +$643K 0.45% 56

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverarc Capital Management's ALXN Position: Q1 2021 in Review

Silverarc Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 5,000 shares — an estimated $781K sold.

Silverarc Capital Management first reported a position in ALXN in Q4 2020 and held it in 1 quarter. The position peaked at $781K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Silverarc Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 5,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $781K.
  • Silverarc Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Silverarc Capital Management's Alexion Pharmaceuticals position peaked at $781K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.